Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topical Insulin for Glaucoma (TING2)
Sponsor: Stanford University
Summary
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma. The study uses a phase 1/2 dose-escalation design followed by a masked, randomized, placebo-controlled phase. Insulin is formulated as preservative-free eye drops and delivered once daily. The primary objective is to determine the safety profile of topical insulin; secondary objectives assess effects on retinal structure, visual field, visual acuity, contrast sensitivity, and quality of life.
Official title: A Phase 1/2 Dose Escalation Followed by a Masked, Randomized, Placebo-Controlled Study to Evaluate Topical Insulin for Neuroprotection in Open Angle Glaucoma
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-06
Completion Date
2029-10
Last Updated
2026-06-02
Healthy Volunteers
No
Conditions
Interventions
EYED-002 Low Dose (721 U/mL topical insulin)
Sterile, preservative-free suspension of Human Insulin USP. One drop to study eye for duration of study group.
EYED-002 High Dose (1442 U/mL topical insulin)
Sterile, preservative-free suspension of Human Insulin USP. One drop to study eye once daily in-clinic for duration of study group.
EYED-002 (highest tolerated dose, 12-month)
Highest tolerated dose of EYED-002 (721 U/mL or 1442 U/mL, determined from Groups 1 and 2 safety review). Once daily at home for 12 months in single-use vials, dispensed at quarterly visits.
Vehicle Placebo
Vehicle-only formulation without active insulin. Single-use vials identical in appearance to active EYED-002. Once daily at home for 12 months.
Locations (1)
Byers Eye Institute at Stanford University
Palo Alto, California, United States